In Reply
We thank Fazio and Milione [1] for their comment on our position paper recently published in The Oncologist [2] . As highlighted in our paper, evidence-based medicine in response to chemotherapy is lacking, and the choice of the best therapeutic option remains a challenge. Fazio and Milione described in their letter that the main primary localization of a welldifferentiated grade 3 neuroendocrine tumor (NET G-3) is the pancreas. They identified in their retrospective cohort that the incidence of pancreatic NET G-3 is 42% of all NET G-3 (10 out of 24). Similarly, in our position paper, we stressed that the main localizations of NET G-3 are the pancreas, the stomach, and the colon.
In addition, we factually reported that there is no validated phase III study on NET G-3 and there are no prospective data ongoing on the targeted therapy efficacy. Furthermore, we agree with their comment that in "low" NET G-3, the proven efficacy of targeted therapy should be evaluated and that in some cases such therapy, either everolimus or sunitinib, should be considered. Fazio and Milione believe that somatostatin receptor-targeted treatments might have a therapeutic efficacy in NET G-3. In 2016, the NETTER-1 phase III study validated the efficacy of the 
